We are live on ! Find out more
PRVL

Prevail Therapeutics Inc. Common Stock
PRVL

Delisted

PRVL was delisted on the 21st of January, 2021.

Back to rankings

67 hedge funds and large institutions have $421M invested in Prevail Therapeutics Inc. Common Stock in 2020 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 25 increasing their positions, 13 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

180% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 5

92% more repeat investments, than reductions

Existing positions increased: 25 | Existing positions reduced: 13

24% more capital invested

Capital invested by funds: $339M → $421M (+$81.8M)

16% more funds holding

Funds holding: 58 → 67 (+9)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

Holders
67
Holders Change
+9
Holders Change %
+15.52%
% of All Funds
1.37%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
14
Increased
25
Reduced
13
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
APM
Avidity Partners Management
Texas
+$15.8M
2
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$13.9M
3
Vanguard Group
Vanguard Group
Pennsylvania
+$5.61M
4
BlackRock
BlackRock
New York
+$4.81M
5
Morgan Stanley
Morgan Stanley
New York
+$4.5M

Top Sellers

Rank Fund Capital Flow
1
EC
EcoR1 Capital
California
-$29M
2
RCM
RA Capital Management
Massachusetts
-$11.5M
3
BI
BVF Inc
California
-$5.26M
4
OFM
Omega Fund Management
Massachusetts
-$1.31M
5
Fidelity Investments
Fidelity Investments
Massachusetts
-$718K
Name Holding Trade Value Shares
Change 		Change in
Stake
N
26
Nuveen
North Carolina
$948K +$214K +13,889 +28%
Jennison Associates
27
Jennison Associates
New York
$911K +$942K +61,161 New
Renaissance Technologies
28
Renaissance Technologies
New York
$858K -$327K -21,205 -27%
Squarepoint
29
Squarepoint
New York
$802K +$565K +36,677 +213%
AS
30
Altshuler Shaham
Israel
$774K – – –
Allianz Asset Management
31
Allianz Asset Management
Germany
$647K +$669K +43,447 New
JP Morgan Chase
32
JP Morgan Chase
New York
$585K +$112K +7,258 +23%
Charles Schwab
33
Charles Schwab
California
$522K +$81.5K +5,290 +18%
Goldman Sachs
34
Goldman Sachs
New York
$482K +$180K +11,712 +57%
California Public Employees Retirement System
35
California Public Employees Retirement System
California
$471K +$487K +31,605 New
SO
36
STRS Ohio
Ohio
$463K +$450K +29,200 +1,537%
AllianceBernstein
37
AllianceBernstein
Tennessee
$362K +$188K +12,200 +101%
Two Sigma Investments
38
Two Sigma Investments
New York
$347K +$45.5K +2,953 +15%
VEA
39
Virtus ETF Advisers
New York
$335K +$346K +22,460 New
State of Wisconsin Investment Board
40
State of Wisconsin Investment Board
Wisconsin
$323K – – –
California State Teachers Retirement System (CalSTRS)
41
California State Teachers Retirement System (CalSTRS)
California
$318K – – –
Verition Fund Management
42
Verition Fund Management
Connecticut
$310K +$320K +20,788 New
Los Angeles Capital Management
43
Los Angeles Capital Management
California
$307K +$116K +7,503 +57%
AC
44
Athanor Capital
New York
$288K +$298K +19,347 New
SG Americas Securities
45
SG Americas Securities
New York
$257K +$266K +17,278 New
Barclays
46
Barclays
United Kingdom
$255K +$111K +7,216 +73%
New York State Common Retirement Fund
47
New York State Common Retirement Fund
New York
$234K +$102K +6,600 +73%
RhumbLine Advisers
48
RhumbLine Advisers
Massachusetts
$224K +$231K +15,016 New
Wells Fargo
49
Wells Fargo
California
$166K -$158K -10,240 -48%
AIG
50
American International Group
New York
$130K +$6.56K +426 +5%
1
2
3

PRVL Hedge Fund Activity: Q2 2020 in Review

67 of the 4,878 institutional investors tracked by Wall St. Rank reported a position in Prevail Therapeutics Inc. Common Stock (PRVL) for Q2 2020, worth a combined $421M — up 24% from $339M a quarter earlier.

Buyers outnumbered sellers: 14 funds opened new PRVL positions and 5 closed out — a net gain of 9 holders — while 25 added to existing stakes and 13 trimmed.

The largest buyer was Avidity Partners Management, opening a new position worth an estimated $15.8M. The largest seller was EcoR1 Capital, cutting an estimated $29M.

  • 67 institutional investors held Prevail Therapeutics Inc. Common Stock (PRVL) as of Q2 2020, up from 58 in Q1 2020.
  • Funds reported $421M of Prevail Therapeutics Inc. Common Stock stock for Q2 2020, up 24% quarter-over-quarter.
  • 14 funds opened new Prevail Therapeutics Inc. Common Stock positions in Q2 2020 and 5 closed out, a net change of +9 holders.
  • The largest Prevail Therapeutics Inc. Common Stock buyer in Q2 2020 was Avidity Partners Management, an estimated $15.8M added.
  • The largest Prevail Therapeutics Inc. Common Stock seller in Q2 2020 was EcoR1 Capital, an estimated $29M sold.

Based on aggregated 13F filings for Q2 2020.